BMT Societies Issue Recommendations on Posttransplant Maintenance in HL/NHL
Use of maintenance therapy as a therapeutic strategy in posttransplant patients with HL and NHL is increasing in frequency
Non-Hodgkin Lymphoma
Severe Neurotoxicity Following CAR-T Cell Therapy Associated With Poor Prognosis
CAR-T–related neurotoxicity was found to be associated with the presence of cytokine release syndrome.
“Real-World” Hospitalization Data on Patients Receiving CAR-T Cell Therapy
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
Ambient Benzene Exposure and Risk of Hematologic Malignancies
Researchers examined low-level estimates of ambient benzene to investigate whether it was associated with increased cancer incidence across a nationwide cohort.
Ibrutinib Plus Nivolumab in 4 Cohorts of Patients With R/R NHL or CLL
According to results of an exploratory study, patients with Richter transformation may benefit from treatment with ibrutinib plus nivolumab.
FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma
Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.
Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma
Findings from a previous study suggested that Q fever may significantly increase a person’s risk of nHL.
Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma
Previous findings showed that patients obinutuzumab plus bendamustine prolonged progression-free survival, but data was immature at the time of analysis.
Poorer DLBCL Survival Outcomes Linked to Dual Expression of MYC, BCL2
Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBCL, though this status was not associated with any outcomes among patients with ABC-like DLBCL.
Next post in Lymphoma
